ATEMPT 2.0: Adjuvant T-DM1 vs TH

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel

Trial Details

NCT ID
NCT04893109
Phase
PHASE2
Sponsor
Dana-Farber Cancer Institute
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • trastuzumab-emtansine
  • Trastuzumab SC
  • Paclitaxel
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Derby, Connecticut, United States|41.32065,-73.089
  • Fairfield, Connecticut, United States|41.14121,-73.26373
  • Glastonbury, Connecticut, United States|41.71232,-72.60815
  • Greenwich, Connecticut, United States|41.02649,-73.62846

Key Eligibility Criteria

  • Patients must have HER2-positive Stage I histologically confirmed invasive carcinoma of the breast. Patients must have node-negative (N0) or microm…
  • If the patient has had a negative sentinel node biopsy, then no further axillary dissection is required, and the patient is determined to be node-n…
  • Any axillary lymph node with tumor clusters between 0.02 and 0.2 cm is considered a micrometastasis. Patients with a micrometastasis are eligible. …
  • Patients who have an area of a T1aN0, ER+ (defined as \>10%), HER2-negative cancer in addition to their primary HER2-positive tumor are eligible.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →